For four decades, the causal link between RAS mutations in cancer – including the KRAS, HRAS, and NRAS genes – has been well-accepted. But for almost as long, oncology drug development has struggled to develop RAS inhibitors, and many had long...

Accelerating the Development of Novel Linebacker Compound

Dedicated Fund Now Open for Private Contributions

Powerful computational tools, such as predictive artificial intelligence (AI) models, are reshaping preclinical research, leading to more optimized and streamlined drug discovery and drug development pipelines.1 In drug discovery, AI can be applied...

Precision oncology (also known as personalized medicine in cancer treatment) is about matching an individual to the optimal therapy for their unique form of cancer. Many people associate personalized medicine with genetic testing. Genomic tumor...

OPTIMIZING BIOMARKER DISCOVERY, MODEL SELECTION AND PRECLINICAL DECISION-MAKING Toronto, ON — April 25, 2023 — In this upcoming live webinar hosted by Xtalks, learn about how artificial intelligence (AI) can bring greater speed and precision to...

Bioinformatics Solution Combines Artificial Intelligence, Maching Learning and Functional Testing to Elevate Precision Cancer Treatment

Presentations to highlight the value of clinically relevant patient-derived xenograft (PDX) models for translational research and drug development

Custom Solutions, Better Translation The ultimate goal of drug development in oncology is to identify drug candidates that will successfully advance through the clinical trial pipeline to FDA approval, thus offering individuals with cancer the hope...

In this educational webinar, learn about the latest innovations in preclinical cancer modeling. This talk will cover advancements in patient-derived xenograft (PDX) development, models of spontaneous metastases and other sophisticated approaches to...